In conclusion, our findings provide real-world clinical evidence that the simultaneous inhibition of EGFR and MET by the combined use of EGFR-TKI and crizotinib is generally tolerable and provides benefit to patients with EGFR-mutant NSCLC who acquired MET amplification-mediated EGFR-TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.